Monoclonal anti‐envelope antibody AP33 protects humanized mice against a patient‐derived hepatitis C virus challenge
Authors:
- Isabelle DesombereIDIsabelle Desombere
- Samira Fafi‐KremerSFSamira Fafi‐Kremer
- Freya Van HoutteFHFreya Van Houtte
- Patrick PessauxPPPatrick Pessaux
- Ali FarhoudiAFAli Farhoudi
- Laura HeydmannLHLaura Heydmann
- Lieven VerhoyeLVLieven Verhoye
- Sarah ColeSCSarah Cole
- Jane A. McKeatingJMJane A. McKeating
- Geert Leroux‐RoelsGLGeert Leroux‐Roels
- Thomas F. BaumertTBThomas F. Baumert
- Arvind H. PatelAPArvind H. Patel
- 21 February 2016
- journal article
- research article
- Published by Wolters Kluwer Health in Hepatology
- Vol. 63 (4) , 1120-1134
Abstract
Gression. Currently available direct‐acting antiviral therapies have reduced efficacy in patients with ESLD and prophylactic strategies to prevent HCV recurrence are still highly needed. In this study, we compared the ability of two broadly reactive monoclonal antibodies (mAbs), designated 3/11 and AP33, recognizing a distinct, but overlapping, epitope in the viral E2 glycoprotein to protect humanized mice from a patient‐derived HCV challenge. Their neutralizing activity was assessed using the HCV pseudoparticles and cell‐culture–derived HCV systems expressing multiple patient‐derived envelopes and a human‐liver chimeric mouse model. HCV RNA was readily detected in all control mice challenged with a patient‐derived HCV genotype 1b isolate, whereas 3 of 4 AP33‐treated mice were completely protected. In contrast, only one of four 3/11‐treated mice remained HCV‐RNA negative throughout the observation period, whereas the other 3 had a viral load that was indistinguishable from that in the control group. The increased in vivo efficacy of AP33 was in line with its higher affinity and neutralizing capacity observed in vitro. Conclusions: Although mAbs AP33 and 3/11 target the same region in E2, only mAb AP33 can efficiently protect from challenge with a heterologous HCV population in vivo. Given that mAb AP33 efficiently neutralizes viral variants that escaped the humoral immune response and reinfected the liver graft of transplant patients, it may be a valuable candidate to prevent HCV recurrence. In addition, our data are valuable for the design of a prophylactic vaccine. (Hepatology 2016;63:1120–1134)...Keywords
Funding Information
- Research Foundation Flanders (G.0212.N, 1.5.009.10N)
- Ghent University (GOA 01G01712)
- Belgian State (IUAP P7/47-HEPRO-2)
- European Union (FP7, ERC-2008-AdG-233130-HEPCENT)
- INTERREG-IV-Rhin Supérieur-FEDER-Hepato-Regio-Net (2009, 2012)
- ANRS (2011/132, 2012/239, 2013/108)
- ANR (ANR-10-LABX-0028_HEPSYS)
- University of Strasbourg Foundation
- National Institute for Health Research Birmingham Liver Biomedical Research Unit
- MRC grant (G1100247)
- eu (FP7)
- PathCO HEALTH (F3-2012-305578)
- Medical Research Council, UK
This publication has 57 references indexed in Scilit:
- Structural basis of hepatitis C virus neutralization by broadly neutralizing antibody HCV1Proceedings of the National Academy of Sciences, 2012
- Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virusProceedings of the National Academy of Sciences, 2012
- Griffithsin Has Antiviral Activity against Hepatitis C VirusAntimicrobial Agents and Chemotherapy, 2011
- A Human Monoclonal Antibody Targeting Scavenger Receptor Class B Type I Precludes Hepatitis C Virus Infection and Viral Spread In Vitro and In VivoHepatology, 2011
- In Vivo Evaluation of the Cross-Genotype Neutralizing Activity of Polyclonal Antibodies Against Hepatitis C Virus ΔσHepatology, 2011
- Viral entry and escape from antibody-mediated neutralization influence hepatitis C virus reinfection in liver transplantationJournal of Experimental Medicine, 2010
- In vitro selection of a neutralization-resistant hepatitis C virus escape mutantProceedings of the National Academy of Sciences, 2008
- Broadly neutralizing human monoclonal antibodies to the hepatitis C virus E2 glycoproteinJournal of General Virology, 2008
- Human combinatorial libraries yield rare antibodies that broadly neutralize hepatitis C virusProceedings of the National Academy of Sciences, 2007
- Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis CProceedings of the National Academy of Sciences, 2007